drug · antibody
empasiprubart
Phase 3updated 3mo agoby $ARGX ARGENX SE🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying empasiprubart
- phase1A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
- phase3A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- phase3A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- —ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- phase2ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- phase3A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
- phase3A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- phase2A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
News(1)
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugArgenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.fiercebiotech · 24d ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that